{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:15:06Z","timestamp":1794266106296,"version":"4.9.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor T (CAR-T) cell therapy has undergone vigorous development in recent years, yet it still faces significant challenges and difficulties in its clinical application and further development. A systematic synthesis of global trends in CAR-T clinical trials is essential to identify knowledge gaps, optimize treatment strategies, and guide future research directions. This review analyzed 1,580 CAR-T clinical trials registered at ClinicalTrials.gov as of April 2024, and extracted characteristic data in multiple dimensions, including target specificity, treatment indication, and development stage etc. The transparency of trial outcomes was assessed by validation with articles published in PubMed\/Google Scholar. Additionally, it is complemented by investigator surveys assessing to barriers to CAR-T development, prospects, and recommendations.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1583116","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:09:33Z","timestamp":1747735773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights"],"prefix":"10.3389","volume":"16","author":[{"given":"Li-Ya","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Chuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Mei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Chuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040531","article-title":"Chimeric antigen receptor T-cell therapy and hematopoiesis","volume":"12","author":"Reinhardt","year":"2023","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00099-9","article-title":"Cancer cell therapies: the clinical trial landscape","volume":"19","author":"Yu","year":"2020","journal-title":"Nat Rev Drug Disco"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic Malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Bloo"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01159-x","article-title":"Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment","volume":"15","author":"Chen","year":"2024","journal-title":"Discover Onc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/v15010202","article-title":"Development of HIV-resistant CAR T cells by CRISPR\/cas-mediated CAR integration into the CCR5 locus","volume":"15","author":"Rothemejer","year":"2023","journal-title":"Virus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1305657","article-title":"Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma","volume":"11","author":"Negishi","year":"2023","journal-title":"Front Pedia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"103020","DOI":"10.1016\/j.copbio.2023.103020","article-title":"Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors","volume":"84","author":"Hong","year":"2023","journal-title":"Curr Opin Biotechn"},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-020-00878-2","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Onc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Onc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2023.0388","article-title":"Current challenges in chimeric antigen receptor T-cell therapy in patients with B-cell lymphoid Malignancies","volume":"44","author":"Kim","year":"2024","journal-title":"Ann Lab Medicin"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lance"},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-024-01568-z","article-title":"Advances in CAR-T-cell therapy in T-cell Malignancies","volume":"17","author":"Zheng","year":"2024","journal-title":"J Hematol Onco"},{"key":"B14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological Malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Re"},{"key":"B15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell Malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol The"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Me"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824208","article-title":"Glypican-3: A novel and promising target for the treatment of hepatocellular carcinoma","volume":"12","author":"Zheng","year":"2022","journal-title":"Front Onco"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Medicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S400013","article-title":"Drug-resistance mechanism and new targeted drugs and treatments of relapse and refractory DLBCL","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancer Manage Re"},{"key":"B20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cance"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389971","article-title":"The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review","volume":"15","author":"Satapathy","year":"2024","journal-title":"Front Immuno"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.3390\/cancers15245852","article-title":"Cytokine modification of adoptive chimeric antigen receptor immunotherapy for glioblastoma","volume":"15","author":"Pawlowski","year":"2023","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13791","article-title":"Revolutionising cancer immunotherapy: advancements and prospects in non-viral CAR-NK cell engineering","volume":"58","author":"Zhou","year":"2025","journal-title":"Cell Prolif"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00759-1","article-title":"EGFRvIII-CAR-T cells with PD-1 knockout have improved anti-glioma activity","volume":"26","author":"Zhu","year":"2020","journal-title":"Pathol Oncol Re"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insigh"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Re"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138473","article-title":"Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02490-9","article-title":"Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy","volume":"23","author":"Tahmasebi","year":"2021","journal-title":"Clin Trans Oncology"},{"key":"B29","article-title":"Development of dual-targeted CAR T-cell therapy","volume":"65","author":"Kato","year":"2024","journal-title":"Rinsho Ketsueki"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commu"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1298","article-title":"Enhancing the potency and specificity of engineered T cells for cancer treatment","volume":"8","author":"Sukumaran","year":"2018","journal-title":"Cancer Discovery"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383894","article-title":"Universal CAR 2.0 to overcome current limitations in CAR therapy","volume":"15","author":"Schlegel","year":"2024","journal-title":"Front Immuno"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Ad"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018658","article-title":"Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy","volume":"143","author":"Tang","year":"2024","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00635-7","article-title":"PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma","volume":"4","author":"Wartewig","year":"2023","journal-title":"Nat Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0022","article-title":"A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma","volume":"12","author":"Chen","year":"2020","journal-title":"Immunotherapy"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"101085","DOI":"10.1016\/j.tranon.2021.101085","article-title":"A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma","volume":"14","author":"Liu","year":"2021","journal-title":"Trans Oncology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01571-5","article-title":"CTLA-4 tail fusion enhances CAR-T antitumor immunity","volume":"24","author":"Zhou","year":"2023","journal-title":"Nat Immuno"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci Trans Me"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2043299","article-title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","volume":"63","author":"Tettamanti","year":"2022","journal-title":"Leukemia Lymphoma"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci Trans Me"},{"key":"B46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10238-024-01365-5","article-title":"MUC16: clinical targets with great potential","volume":"24","author":"Zhang","year":"2024","journal-title":"Clin Exp Me"},{"key":"B47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-025-00638-3","article-title":"Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults","volume":"14","author":"Gal\u00e1n-G\u00f3mez","year":"2025","journal-title":"Exp Hematol Onco"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013688","article-title":"Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood Ad"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Me"},{"key":"B50","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00262-024-03661-1","article-title":"Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"73","author":"Ma","year":"2024","journal-title":"Cancer Immunology Immunotherap"},{"key":"B52","doi-asserted-by":"publisher","first-page":"04204","DOI":"10.7189\/jogh.14.04204","article-title":"Academic vs. industry-sponsored trials: A global survey on differences, similarities, and future improvements","volume":"14","author":"Hoffmann","year":"2024","journal-title":"J Global Healt"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Onco"},{"key":"B54","doi-asserted-by":"publisher","first-page":"103239","DOI":"10.1016\/j.critrevonc.2021.103239","article-title":"Chimeric antigen receptor T cell therapy in oncology \u2013 Pipeline at a glance: Analysis of the ClinicalTrials.gov database","volume":"159","author":"Moreno-Cortes","year":"2021","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Medicine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"217083","DOI":"10.1016\/j.canlet.2024.217083","article-title":"The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx","volume":"597","author":"Zhou","year":"2024","journal-title":"Cancer Let"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res The"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02188-0","article-title":"Cost-effectiveness of chimeric antigen receptor T cell therapy in patients with relapsed or refractory large B cell lymphoma: no impact of site of care","volume":"39","author":"Cummings Joyner","year":"2022","journal-title":"Adv The"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lance"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1583116\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:09:35Z","timestamp":1747735775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1583116\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2025.1583116"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1583116","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2025.1583116.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"article-number":"1583116"}}